Ltd.

Meihua International Medical Technologies Co., Ltd.’s Subsidiary to Attend and Showcase 12 New Products at the 87th China International Medical Equipment Fair

by

YANGZHOU, China, May 15, 2023 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced that its wholly-owned subsidiary, Jiangsu Huadong Medical Device Industrial Co., Ltd. (“Jiangsu Huadong”), has been invited … Read more

MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project

by

SHENZHEN, China, May 15, 2023 /PRNewswire/ — MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, recently shared that a total of nearly 60,000 samples have been sequenced among 21 institutes and over 10 participating nations throughout Europe, as part of the Million Microbiome of Humans … Read more

Ergebnisse der klinischen Phase-I-Studie mit dem bifunktionalen PD-1/CTLA-4-Antikörper Iparomlimab/Tuvonralimab von Qilu Pharma wurden online im Journal of Hematology & Oncology veröffentlicht USA – Deutsch APAC – English USA – English USA – español

by

JINAN, China, 12. Mai 2023 /PRNewswire/ — Am 8. Mai 2023 veröffentliche das Journal of Hematology & Oncology (JHO, 2022 Impact Factor von 23.168) die Ergebnisse der klinischen Phase-I-Studie des bifunktionalen Immuntherapie-Antikörpers QL1706 von Qilu Pharma (J Hematol Oncol 8. Mai 2023;16(1):50). Diese Studie ist die erste große klinische Phase-I-Studie mit QL1706 am Menschen und … Read more

Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 de Qilu Pharma

by

-Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 Iparomlimab/Tuvonralimab de Qilu Pharma publicado en línea en Journal of Hematology & Oncology JINAN, China, 12 de mayo de 2023 /PRNewswire/ — El 8 de mayo de 2023, Journal of Hematology & Oncology (JHO, 2022 factor de impacto de 23.168) publicó los resultados del … Read more

Results of Phase I Clinical Study of Qilu Pharma’s PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology USA – English APAC – English

by

JINAN, China, May 12, 2023 /PRNewswire/ — On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma’s immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023 May 8;16(1):50). This study is the first large Phase I clinical trial of … Read more

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

by

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year─ ─Advancing Phase 2 PSC Trial and Enrolling Patients in Higher Dose Cohort ─ ─Extending Estimated Cash Runway … Read more